快速进展性IgA肾病:根据KDIGO 2021指南修订定义评估的临床病理特征与结局
在1677例中国单中心IgA肾病患者中评估KDIGO 2021指南快速进展性IgA肾病新定义(eGFR≤3个月内下降≥50%)的效用。仅2.3%(39/1677)符合该定义,其进展至终末期肾病的风险显著高于非快速进展性患者(logrank P<0.001),且为独立危险因素(HR 3.99,95%CI 2.25-7.09;P<0.001)。数据支持该定义的有效性,但需在非中国队列中独立验证。
要点
- eGFR≤3个月内下降≥50%者占5.2%,其中多数为可逆原因,仅2.3%符合KDIGO 2021快速进展性IgA肾病定义。
- 快速进展性IgA肾病是终末期肾病的独立危险因素(HR 3.99,95%CI 2.25-7.09;P<0.001)。
- 快速进展性患者中仅25.6%有≥50%新月体,有无≥50%新月体者终末期肾病风险无显著差异(logrank P=0.27)。
核心结论
- 数据支持KDIGO 2021快速进展性IgA肾病定义的有效性,但需在非中国队列中独立验证。
研究设计与样本
- 在中国单中心随访的1677例IgA肾病患者中,评估KDIGO 2021指南新定义(eGFR≤3个月内下降≥50%)识别最高危、可能适合联合免疫抑制治疗患者的作用。
主要发现
- eGFR≤3个月内下降≥50%者占5.2%,其中多数为可逆原因,仅2.3%(39/1677)符合KDIGO 2021快速进展性IgA肾病标准。
- 快速进展性IgA肾病患者终末期肾病风险显著高于非快速进展性患者(logrank P<0.001)。
- 快速进展性IgA肾病是终末期肾病的独立危险因素(HR 3.99,95%CI 2.25-7.09;P<0.001)。
- 快速进展性患者中仅25.6%有≥50%新月体;有无≥50%新月体者终末期肾病风险无显著差异(logrank P=0.27)。
- 快速进展性且≥50%新月体患者终末期肾病风险高于非快速进展性且≥50%新月体患者(logrank P=0.04)。
关键数值与推荐
- KDIGO 2021指南快速进展性IgA肾病定义:eGFR在≤3个月内下降≥50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需在非中国队列中独立验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rapidly progressive immunoglobulin A nephropathy (RPIgAN) is a severe clinical phenotype of IgAN associated with a poor outcome. The recently published Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Guideline for the Management of Glomerular Diseases has proposed a new definition for RPIgAN that is based simply on a ≥50% decline in the estimated glomerular filtration rate (eGFR) over ≤3 months. METHODS: In 1677 IgAN patients followed at a single centre in China, we evaluated the utility of this new definition to identify the highest-risk IgAN patients who might be suitable for combination immunosuppressive therapy. RESULTS: The proportion of a ≥50% decline in eGFR over ≤3 months was 5.2%. The majority of these patients had reversible causes, with only 2.3% (39/1677) meeting the KDIGO 2021 criteria for RPIgAN. These patients had a significantly higher risk for end-stage kidney disease (ESKD) than non-RPIgAN patients (logrank P < 0.001). RPIgAN was an independent risk factor for ESKD [hazard ratio 3.99 (95% confidence interval 2.25-7.09); P <0.001]. A minority of the RPIgAN patients (25.6%) had ≥50% crescents. There was no significant difference in the risk for ESKD between patients in the RPIgAN group with ≥50% crescents and ˂50% crescents (logrank P = 0.27). Patients with RPIgAN and ≥50% crescents had a higher risk for ESKD than patients with non-RPIgAN and ≥50% crescents (logrank P = 0.04). CONCLUSIONS: These data support the validity of the KDIGO 2021 definition but require independent validation in other non-Chinese cohorts.
引用
- Yu B, Shi S, Lv J, et al. Rapidly progressive IgA nephropathy: clinicopathological characteristics and outcomes assessed according to the revised definition of the KDIGO 2021 Guideline. Nephrol Dial Transplant. 2022. PMID: 35020934. doi:10.1093/ndt/gfac004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。